A Prospective Randomized Study of Irinotecan (CPT-11), Leucovorin (LV) and 5-Fluorouracil (5FU) versus Leucovorin and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma

References

• Rustum YM, Harstrick A, Cao S, et al. Thymidylate syn-thase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997; 15: 389–400.
   PubMed Web of Science ®Google Scholar
• Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcino-ma. Cancer 1997; 80: 1179-1187.
   Google Scholar
• Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418.
   PubMed Web of Science ®Google Scholar
• Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest OncologyGroup study. J Clin Oncol 1995; 13: 1303–1311.
   PubMed Web of Science ®Google Scholar
• Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14–20.
   PubMed Web of Science ®Google Scholar
• O'Connell MJ. A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluo-rouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group. Adv Exp Med Biol 1988; 244: 173–84.
   PubMedGoogle Scholar
• Jaxel C, Kohn KW, Wani MC et al. Structure-activity study of the actions of camptothecin derivatives on mam-malian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989; 49: 1465-1469.
   Google Scholar
• Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mam-malian DNA topoisomerase I. J Biol Chem 1985; 260: 14 873–8.
   PubMed Web of Science ®Google Scholar
• Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan article (CPT-11) is an active agent in untreated patients with metastatic col-orectal cancer. J Clin Oncol 1995; 14: 709–718.
   Web of Science ®Google Scholar
• Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecanin the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260.
   PubMed Web of Science ®Google Scholar
• Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905–914.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluo-rouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–1047.
   PubMed Web of Science ®Google Scholar
• Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorec-tal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005 Aug 1; 23 (22): 4856–4865.
   PubMed Web of Science ®Google Scholar
• Bouzid K, Khalfallah S, Tujakowski J, et al. A random-ized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol 2003; 14: 1106-1114.
   Google Scholar
• Kalofonos HP, Skarlos D, Bafaloukos D, et al. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluo-rouracil in patients with advanced colorectal carcinoma. Cancer Invest. 2003; 21 (6): 855–862.
   PubMed Web of Science ®Google Scholar
• Coto A, Yamada Y, Hosokawa A, et al. Phase I/II study of irinotecan, 5-fluorouracil, and 1-leucovorin combina-tion therapy (modified Saltz regimen) in patients with metasta-tic colorectal cancer. Int J Clin Oncol 2004; 9: 364–368.
   PubMedGoogle Scholar
• Perry MC. National Cancer Institute Common Toxicity Criteria: the chemotherapy source book. Baltimore, MD; Williams & Wilkins; 1990: 1133-1140.
   Google Scholar
• Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163–170.
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308.
   Google Scholar
• Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998; 55: 667–676.
   PubMed Web of Science ®Google Scholar
• Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, anew camptothecin derivative, in metastatic col-orectal cancer. J Clin Oncol 1993; 11: 909–913.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecanin patients with progressive or rapidly recur-rent colorectal cancer. J Clin Oncol 1996; 14: 1128–1135.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413–1418.
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure inpatients with metastatic colorectal cancer. Lancet 1998; 352: 1407–1412. [Erratum,Lancet 1998; 352: 1634.]
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leu-covorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801–3807
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;3 5: 144–145
   Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI fol-lowed by FOLFOX6 or the reverse sequence in advanced col-orectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–237
   PubMed Web of Science ®Google Scholar
• Borner MM, Bernhard J, Dietrich D, et al. A random-ized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005; 16 (2): 282–288.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350 (23): 2335-2342.3°
   Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351 (4): 337–345.
   PubMed Web of Science ®Google Scholar